Gilead Sciences (GILD) agreed to pay nearly $97 million to resolve allegations that donations it paid to a charity were actually kickbacks to Medicare patients used to cover out-of-pockets costs for its medicine used to treat a type of high blood pressure.

This is only the latest instance in which federal authorities have cracked down on such arrangements between drug makers and patient assistance charities.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Don’t all of the pharma companies do this? Our oncology patients get foundation help for paying for their expensive oral medications and those foundations are sponsored by pharma. How is Gilead different that this?

    • Hi David,

      Thanks for writing in. And yes, federal authorities have extracted settlements from numerous drug makers over the past year for the same alleged practices. Do a search on our site using the words ‘Medicare,’ ‘kickback’ and ‘foundation,’ and you’ll see what I mean.

      So in that way, Gilead isn’t any different than the others.

      All best
      ed at pharmalot

  • calling a treatment for pulmonary arterial hypertension a type of blood pressure medication is perhaps technically correct but IMO wildly misleading and uninformed

    • Hi TW,

      Thanks for the note.
      And yes, in the lead sentence, I opted for a quick description.

      The focus of the story was on the alleged practices. Many companies have been tagged by federal authorities for the same thing involving all sorts of drugs for all sorts of maladies.

      Nonetheless, yes, I could have added a line later explaining PAH in a little more detail. There was no attempt to mislead. The alleged violations were serious regardless of the illness involved.

      Hope this helps,
      ed at pharmalot

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy